{"groups":[{"description":"Abraxane 220 mg/m\\^2 intravenously on Day 1 of 21 day cycle.","id":"FG000","title":"Abraxane"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Inadequate Trial"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Hospice"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: November 2012 to October 2015. All recruitment done at The University of Texas MD Anderson Cancer Center."}